- Home
- STRO vs GECC Comparison
STRO vs GECC Comparison
Compare STRO & GECC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- GECC
- Stock Information
- Founded
- STRO 2003
- GECC 2016
- Country
- STRO United States
- GECC United States
- Employees
- STRO N/A
- GECC N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- GECC Finance: Consumer Services
- Sector
- STRO Health Care
- GECC Finance
- Exchange
- STRO Nasdaq
- GECC Nasdaq
- Market Cap
- STRO 147.6M
- GECC 120.9M
- IPO Year
- STRO 2018
- GECC N/A
- Fundamental
- Price
- STRO $1.77
- GECC $11.12
- Analyst Decision
- STRO Strong Buy
- GECC
- Analyst Count
- STRO 7
- GECC 0
- Target Price
- STRO $12.14
- GECC N/A
- AVG Volume (30 Days)
- STRO 950.7K
- GECC 12.0K
- Earning Date
- STRO 03-24-2025
- GECC 03-03-2025
- Dividend Yield
- STRO N/A
- GECC 13.22%
- EPS Growth
- STRO N/A
- GECC N/A
- EPS
- STRO N/A
- GECC 0.65
- Revenue
- STRO $160,955,000.00
- GECC $39,468,000.00
- Revenue This Year
- STRO N/A
- GECC $17.68
- Revenue Next Year
- STRO N/A
- GECC $4.96
- P/E Ratio
- STRO N/A
- GECC $17.09
- Revenue Growth
- STRO 230.90
- GECC 16.86
- 52 Week Low
- STRO $1.51
- GECC $9.55
- 52 Week High
- STRO $6.13
- GECC $11.34
- Technical
- Relative Strength Index (RSI)
- STRO 42.89
- GECC 65.72
- Support Level
- STRO $1.76
- GECC $10.45
- Resistance Level
- STRO $1.95
- GECC $11.34
- Average True Range (ATR)
- STRO 0.13
- GECC 0.23
- MACD
- STRO 0.00
- GECC 0.05
- Stochastic Oscillator
- STRO 41.94
- GECC 77.25
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
About GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. The company seeks to generate current income and capital appreciation through debt and equity investments, including investments in specialty finance businesses. It invests in senior secured and senior unsecured debt instruments, as well as in junior loans and mezzanine debt of middle-market companies and small businesses. The company generates revenue from interest on the debt investments that it holds.